GlassScriptPhysician profile
Anjula Gandhi
NPI 1790729671
$3,828.95
in general payments reported to CMS, 2019-2025
23 companies · $203 in 2025
The $203 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $947 · 2020: $401 · 2021: $1,055 · 2022: $329 · 2023: $419 · 2024: $475 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,026.28 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $537.91 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $490.15 | 2019-2023 | Eliquis |
| Abbvie INC. | $354.50 | 2021-2025 | |
| Pfizer INC. | $312.42 | 2019-2023 | |
| Kestra Medical Technology Services, INC. | $253.65 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $147.25 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $116.07 | 2019-2023 | Breztri |
| Novartis Pharmaceuticals Corporation | $87.34 | 2019 | |
| Daiichi Sankyo INC. | $60.25 | 2019 | |
| Philips North America LLC | $59.80 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.09 | 2019 | |
| Amgen INC. | $43.97 | 2019-2021 | |
| Allergan, INC. | $35.54 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.40 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.43 | 2025 | Cardiomems |
| Scpharmaceuticals INC. | $30.81 | 2024 | |
| Phadia US INC. | $30.65 | 2019 | |
| Eisai INC. | $28.46 | 2025 | |
| Sk Life Science, INC. | $26.07 | 2023 | |
| Electromed, INC. | $22.65 | 2019 | |
| Global Blood Therapeutics, INC. | $21.31 | 2021 | |
| Celgene Corporation | $20.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjula Gandhi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.